stockmarketproxy
/
BMRNNasdaq SEC EDGAR

BIOMARIN PHARMACEUTICAL INC

Pharmaceutical Preparations·NOVATO, CA·FY end 12/31·CIK 1048477
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$3.2B$2.9B$2.4B$2.1B$1.8B
Gross Profit——————
Operating Income$409.5M$484.2M$158.1M$149.6M-$82.3M
Net Income$348.9M$426.9M$167.6M$141.6M-$64.1M
Operating CF$828.0M$572.8M$159.3M$175.9M$304.5M
Capex$103.0M$85.4M$96.7M$121.0M$95.6M
Free Cash Flow$725.0M$487.4M$62.6M$54.9M$209.0M
Buybacks———$0$0
Dividends——————
Gross Margin——————
Operating Margin12.7%17.0%6.5%7.1%-4.5%
Net Margin10.8%15.0%6.9%6.8%-3.5%
FCF Margin22.5%17.1%2.6%2.6%11.3%
R&D / Revenue28.6%26.2%30.9%31.0%34.1%
Effective Tax27.7%21.2%11.1%5.4%15.0%
Debt / Equity——————
Buybacks / FCF———0.0%0.0%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
BMRN
109:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
BMRN
$22M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
BMRN
10.8%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%